M
Michael E. Williams
Researcher at University of Virginia
Publications - 139
Citations - 11624
Michael E. Williams is an academic researcher from University of Virginia. The author has contributed to research in topics: Mantle cell lymphoma & Rituximab. The author has an hindex of 39, co-authored 133 publications receiving 10879 citations. Previous affiliations of Michael E. Williams include University of Rochester & Harvard University.
Papers
More filters
Journal ArticleDOI
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
Peter McLaughlin,Antonio J. Grillo-Lopez,Brian K. Link,Ronald Levy,Myron S. Czuczman,Michael E. Williams,M R Heyman,I. Bence-Bruckler,Christine A. White,Fernando Cabanillas,Vinay K. Jain,A D Ho,John Lister,K Wey,D. Shen,Brian Dallaire +15 more
TL;DR: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar,Susanna Jacobus,Natalie S. Callander,Rafael Fonseca,David H. Vesole,Michael E. Williams,Rafat Abonour,David S. Siegel,Michael S. Katz,Philip R. Greipp +9 more
TL;DR: Lenalidomide plus low-dose dexamethasone is associated with better short-term overall survival and with lower toxicity than lenalidomid plus high-dose DexamethAsone in patients with newly diagnosed myeloma in this open-label non-inferiority trial.
Journal ArticleDOI
Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma
K. Sue Robinson,Michael E. Williams,Richard van der Jagt,Philip R. Cohen,Jordan A. Herst,Anil Tulpule,Lee S. Schwartzberg,Bernard Lemieux,Bruce D. Cheson +8 more
TL;DR: Bendamustine plus rituximab is an active combination in patients with relapsed indolent and mantle cell lymphoma and was generally well tolerated; the primary toxicity was myelosuppression.
Journal ArticleDOI
Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
Adam D. Kennedy,Paul V. Beum,Michael D. Solga,David J. DiLillo,Margaret A. Lindorfer,Charles E. Hess,John J. Densmore,Michael E. Williams,Ronald P. Taylor +8 more
TL;DR: In vitro studies indicate that at high cell densities, binding of rituximab to human CD20+ cells leads to loss of complement activity and consumption of component C2, and western blots provide additional evidence for this escape mechanism that appears to occur as a consequence of CD20 loss.